Results 151 to 160 of about 10,843,123 (260)

Proteoforms in Disease: Biomedical Applications of Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The proteome is a dynamic landscape of proteoforms arising from genetic mutations, alternative splicing, and post‐translational modifications (PTMs), which collectively drive biological function and disease phenotypes. Mass spectrometry (MS)‐based proteomics has emerged as an essential technique for elucidating this molecular complexity ...
Holden T. Rogers, Zachery R. Gregorich, Megan S. Gant, Zhan Gao, Julia Chamot‐Rooke, Ying Ge   +5 more
wiley   +1 more source

Multiomics Insights Into AL Amyloidosis

Medicine Bulletin, EarlyView.
ABSTRACT Light chain amyloidosis is a systemic or localized protein conformational disorder triggered by misfolded immunoglobulin light chains, leading to amyloid fibril deposition. The disease is characterized by multiorgan involvement and delayed diagnosis, contributing to poor prognosis and high mortality rates.
Zixuan Zhang, Ziru Huang, Haoxiang Tang, Xianrun Pan, Rong Wang, Dingding Zhang, Jian Huang   +6 more
wiley   +1 more source

Harnessing Aggregation‐Induced Emission for Advanced Disease Diagnosis: Mechanisms, Strategies and Future Perspectives

Medicine Bulletin, EarlyView.
The figure was created in BioRender.com. ABSTRACT Accurate and early diagnosis remains a key challenge in modern disease management. Conventional diagnostic methods often suffer from limitations in sensitivity, spatial resolution, and practical usability.
Zizhuo Du, Li Song, Xingrui Chen, Jun Jing, Yingchen Wang, Yue Jiang, Jiahui Gao, Dan Li, Feiran Xie, Peihong Xiao, Ben Zhong Tang   +10 more
wiley   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

Med Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu, Weiquan Liao, Ziqi Lian, Mengdan Zhang, Chenxing Wang, Xingjia Zhu, Lin Zhang, Jian Chen, Zhichao Lu, Peipei Gong   +9 more
wiley   +1 more source

Association Between Plasma Phosphorylated Tau‐217 and Cognition in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Alzheimer's disease (AD) co‐pathology contributes to dementia in PD, but its role in earlier cognitive impairment remains uncertain. Objective To determine if p‐tau217, a biomarker of early AD, is associated with cognitive impairment in PD.
Trycia Kouchache, Tevy Chan, Sophie Sun, Lang Liu, Aline Delva, Ziv Gan‐Or, Pedro Rosa‐Neto, Jean‐François Gagnon, Alain Dagher, Ronald B. Postuma, Madeleine Sharp   +10 more
wiley   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. [PDF]

Alzheimers Dement
Tonietto M, Silvestri E, Belder CRS, Barkhof F, Fox NC, Smith J, Klein G.   +6 more
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab. [PDF]

Neurocase
Schwartz NU, Dietz CD, Lin Z, Tammewar G, Bui N, La Joie R, Wang Y, Sreekrishnan A, Suhami D, VandeVrede L, Ljubenkov PA, Rojas JC.   +11 more
europepmc   +1 more source